Last updated: July 7, 2024
Sponsor: Rhode Island Hospital
Overall Status: Active - Recruiting
Phase
4
Condition
Knee Replacement
Treatment
Lidocaine IV
Saline IV
Clinical Study ID
NCT04828083
1617319
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- ASA PS 1-3 patients undergoing primary, unilateral total knee arthroplasty
Exclusion
Exclusion Criteria:
ASA PS classification of 4 or greater
Pre-existing neuropathy
Coagulopathy
Chronic opioid consumption (>3 months)
Infection at the site
Known allergy to study medications (lidocaine)
High grade atrioventricular block (cardiac conduction system impairment)
A history of CVA/TIA
Currently using lidocaine patches
Known liver disease
Study Design
Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Lidocaine IV
Phase: 4
Study Start date:
March 01, 2021
Estimated Completion Date:
November 30, 2024
Study Description
Connect with a study center
Rhode Island Hospital
Providence, Rhode Island 02903
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.